Pathophysiology of cyclooxygenases in cardiovascular homeostasis

Veterinary Pathology

Volumn 47, Issue 4, 2010, Pages 601-613

  Sellers, Rani S ^a   Radi, Z A ^b   Khan, N K ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Cardiovascular; COX 1; COX 2; Cyclooxygenase; Nonselective nonsteroidal anti inflammatory drugs; NSAIDs; Selective nonsteroidal anti inflammatory drugs

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL; ARTICLE; CARDIOVASCULAR SYSTEM; DRUG EFFECT; HOMEOSTASIS; HUMAN; METABOLISM; MOUSE; DRUG EFFECTS;

ANIMALS; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HOMEOSTASIS; HUMANS; MICE;

RODENTIA;

EID: 77954920270     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985810364389     Document Type: Article

References (117)

1. Abbate A., Salloum FN, Ockaili RA, Fowler AA III, Biondi-Zoccai GG, Straino S., Lipinski MJ, Baldi A., Crea F., Biasucci LM, Vetrovec GW, Kukreja RC: Improvement of cardiac function with parecoxib, a cyclo-oxygenase-2 inhibitor, in a rat model of ischemic heart failure. J Cardiovasc Pharmacol 49:416-418, 2007.
2. Abbate A., Santini D., Biondi-Zoccai GG, Scarpa S., Vasaturo F., Liuzzo G., Bussani R., Silvestri F., Baldi F., Crea F., Biasucci LM, Baldi A.: Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe? Heart 90:440-443, 2004.
3. Aitchison KA, Coker SJ: Cyclooxygenase inhibition converts the effect of nitric oxide synthase inhibition from infarct size reduction to expansion in isolated rabbit hearts. J Mol Cell Cardiol 31:1315- 1324, 1999.
4. Alcindor D., Krolikowski JG, Pagel PS, Warltier DC, Kersten JR: Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology 100:547-554, 2004.
5. Alhaddad IA, Tkaczevski L., Siddiqui F., Mir R., Brown EJ Jr: Aspirin enhances the benefits of late reperfusion on infarct shape: a possible mechanism of the beneficial effects of aspirin on survival after acute myocardial infarction. Circulation 91:2819- 2823, 1995.
6. Athirakul K., Kim HS, Audoly LP, Smithies O., Coffman TM: Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int 60:2324-2329, 2001.
7. Bea F., Blessing E., Bennett BJ, Kuo CC, Campbell LA, Kreuzer J., Rosenfeld ME: Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 60:198-204, 2003.
8. Belton O., Byrne D., Kearney D., Leahy A., Fitzgerald DJ: Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102:840-845, 2000.
9. Belton OA, Duffy A., Toomey S., Fitzgerald DJ: Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108:3017-3023, 2003.
10. Birck R., Krzossok S., Knoll T., Braun C., van Der Woude FJ, Rohmeiss P.: Preferential COX-2 inhibitor, meloxicam, compromises renal perfusion in euvolemic and hypovolemic rats. Exp Nephrol 8:173-180, 2000.
11. Black SC, Brideau C., Cirino M., Belley M., Bosquet J., Chan CC, Rodger IW: Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs. J Cardiovasc Pharmacol 32:686-694, 1998.
12. Bolli R., Goldstein RE, Davenport N., Epstein SE: Influence of sulfinpyrazone and naproxen on infarct size in the dog. Am J Cardiol 47:841-847, 1981.
13. Brands MW, Hailman AE, Fitzgerald SM: Long-term glucose infusion increases arterial pressure in dogs with cyclooxygenase-2 inhibition. Hypertension 37:733-738, 2001.
14. Brown EJ Jr, Kloner RA, Schoen FJ, Hammerman H., Hale S., Braunwald E.: Scar thinning due to ibuprofen administration after experimental myocardial infarction. Am J Cardiol 51:877-883, 1983.
15. Burleigh ME, Babaev VR, Patel MB, Crews BC, Remmel RP, Morrow JD, Oates JA, Marnett LJ, Fazio S., Linton MF: Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice. Biochem Pharmacol 70:334- 342, 2005.
16. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S., Linton MF: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoEdeficient and C57BL/6 mice. J Mol Cell Cardiol 39:443-452, 2005.
17. Campbell CL, Smyth S., Montalescot G., Steinhubl SR: Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297:2018-2024, 2007.
18. Carnieto A., Jr., Dourado PM, da Luz PL, Chagas AC: Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. Clinics (Sao Paulo) 64:245-252, 2009.
19. Chan CC, Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R., Gresser M., Guay J., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neill GP, Ouellet M., Patrick D., Percival MD, Perrier H., Prasit P., Rodger I.: Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor: pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551-560, 1999.
20. Chenevard R., Hurlimann D., Bechir M., Enseleit F., Spieker L., Hermann M., Riesen W., Gay S., Gay RE, Neidhart M., Michel B., Luscher TF, Noll G., Ruschitzka F.: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107:405-409, 2003.
21. Cheng Y., Austin SC, Rocca B., Koller BH, Coffman TM, Grosser T., Lawson JA, FitzGerald GA: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539-541, 2002.
22. Cipollone F., Fazia ML: Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk. Curr Atheroscler Rep 8:245-251, 2006.
23. Cryer B., Feldman M.: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104:413-421, 1998.
24. Cuenca J., Martin-Sanz P., Alvarez-Barrientos AM, Bosca L., Goren N.: Infiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis. Am J Pathol 169:1567-1576, 2006.
25. Cyrus T., Yao Y., Ding T., Dogne JM, Pratico D.: Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood 109:3291- 3296, 2007.
26. Cyrus T., Yao Y., Tung LX, Pratico D.: Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. Atherosclerosis 184:8-14, 2006.
27. Dannenberg AJ, Altorki NK, Boyle JO, Dang C., Howe LR, Weksler BB, Subbaramaiah K.: Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544-551, 2001.
28. Degousee N., Fazel S., Angoulvant D., Stefanski E., Pawelzik SC, Korotkova M., Arab S., Liu P., Lindsay TF, Zhuo S., Butany J., Li RK, Audoly L., Schmidt R., Angioni C., Geisslinger G., Jakobsson PJ, Rubin BB: Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 117:1701-1710, 2008.
29. Delgado RM III, Nawar MA, Zewail AM, Kar B., Vaughn WK, Wu KK, Aleksic N., Sivasubramanian N., McKay K., Mann DL, Willerson JT: Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 109:1428-1433, 2004.
30. Dilger K., Herrlinger C., Peters J., Seyberth HW, Schweer H., Klotz U.: Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol 42:985-994, 2002.
31. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378:406-409, 1995.
32. Dowd NP, Scully M., Adderley SR, Cunningham AJ, Fitzgerald DJ: Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108:585-590, 2001.
33. Egan KM, Wang M., Fries S., Lucitt MB, Zukas AM, Pure E., Lawson JA, FitzGerald GA: Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111:334-342, 2005.
34. Eling TE, Thompson DC, Foureman GL, Curtis JF, Hughes MF: Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 30:1-45, 1990.
35. Estrela JM, Montoro JB, Vina JR, Vina J.: Glutathione metabolism under the influence of hydroperoxides in the lactating mammary gland of the rat: effect of glucose and extracellular ATP. Biosci Rep 7:23-31, 1987.
36. Ferdinandy P., Schulz R., Baxter GF: Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59:418-458, 2007.
37. Fiedler VB, Mardin M.: Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog. J Cardiovasc Pharmacol 7:983-989, 1985.
38. Fitzgerald GA: Prostaglandins: modulators of inflammation and cardiovascular risk. J Clin Rheumatol 10:S12-S17, 2004.
39. Flynn PJ, Becker WK, Vercellotti GM, Weisdorf DJ, Craddock PR, Hammerschmidt DE, Lillehei RC, Jacob HS: Ibuprofen inhibits granulocyte responses to inflammatory mediators: a proposed mechanism for reduction of experimental myocardial infarct size. Inflammation 8:33-44, 1984.
40. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R., Ruijne N.: The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101:1060-1063, 2008.
41. Gres P., Schulz R., Jansen J., Umschlag C., Heusch G.: Involvement of endogenous prostaglandins in ischemic preconditioning in pigs. Cardiovasc Res 55:626-632, 2002.
42. Gross GJ, Moore J.: Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine. Pharmacology 71:135-142, 2004.
43. Gross S., Tilly P., Hentsch D., Vonesch JL, Fabre JE: Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 204:311-320, 2007.
44. Guo Y., Bao W., Wu WJ, Shinmura K., Tang XL, Bolli R.: Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res Cardiol 95:479-484, 2000.
45. Hammerman H., Kloner RA, Schoen FJ, Brown EJ Jr, Hale S., Braunwald E.: Indomethacin-induced scar thinning after experimental myocardial infarction. Circulation 67:1290-1295, 1983.
46. Hartner A., Cordasic N., Goppelt-Struebe M., Veelken R., Hilgers KF: Role of macula densa cyclooxygenase-2 in renovascular hypertension. Am J Physiol Renal Physiol 284:F498-502, 2003.
47. Heindl B., Becker BF: Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates postischaemic cardiac dysfunction, independent of COX function. Naunyn Schmiedebergs Arch Pharmacol 363:233-240, 2001.
48. Hennan JK, Huang J., Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR: Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104:820-825, 2001.
49. Hermann M., Shaw S., Kiss E., Camici G., Buhler N., Chenevard R., Luscher TF, Grone HJ, Ruschitzka F.: Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 45:193-197, 2005.
50. Hocherl K., Endemann D., Kammerl MC, Grobecker HF, Kurtz A.: Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol 136:1117-1126, 2002.
51. Hohlfeld T., Strobach H., Schror K.: Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury. J Pharmacol Exp Ther 264:397-405, 1993.
52. Hong BK, Kwon HM, Lee BK, Kim D., Kim IJ, Kang SM, Jang Y., Cho SH, Kim HK, Jang BC, Cho SY, Kim HS, Kim MS, Kwon HC, Lee N.: Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 41:82-88, 2000.
53. Hong TT, Huang J., Barrett TD, Lucchesi BR: Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am J Physiol Heart Circ Physiol 294:145-155, 2008.
54. Innes IR, Weisman H.: Reduction in the severity of myocardial infarction by sulfinpyrazone. Am Heart J 102:153-157, 1981.
55. Inserte J., Molla B., Aguilar R., Traves PG, Barba I., Martin-Sanz P., Bosca L., Casado M., Garcia-Dorado D.: Constitutive COX-2 activity in cardiomyocytes confers permanent cardioprotection Constitutive COX-2 expression and cardioprotection. J Mol Cell Cardiol 46:160-168, 2009.
56. Jalowy A., Schulz R., Dörge H., Behrends M., Heusch G.: Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32:1787-1796, 1998.
57. Jugdutt BI, Hutchins GM, Bulkley BH, Pitt B., Becker LC: Effect of indomethacin on collateral blood flow and infarct size in the conscious dog. Circulation 59:734-743, 1979.
58. Kawada N., Solis G., Ivey N., Connors S., Dennehy K., Modlinger P., Hamel R., Kawada JT, Imai E., Langenbach R., Welch WJ, Wilcox CS: Cyclooxygenase-1-deficient mice have high sleep-to-wake blood pressure ratios and renal vasoconstriction. Hypertension 45:1131-1138, 2005.
59. Kawka DW, Ouellet M., Hetu PO, Singer, II, Riendeau D.: Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochim Biophys Acta 1771:45-54, 2007.
60. Kay-Mugford PA, Benn SJ, LaMarre J., Conlon PD: Cyclooxygenase expression in canine platelets and Madin-Darby canine kidney cells. Am J Vet Res 61:1512-1516, 2000.
61. Kearney D., Byrne A., Crean P., Cox D., Fitzgerald DJ: Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 43:526-531, 2004.
62. Khan KN, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL, Trump BF, Maziasz TJ, Alden CL: Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 26:612-620, 1998.
63. Kim JW, Baek BS, Kim YK, Herlihy JT, Ikeno Y., Yu BP, Chung HY: Gene expression of cyclooxygenase in the aging heart. J Gerontol A Biol Sci Med Sci 56:350-355, 2001.
64. Kobayashi T., Tahara Y., Matsumoto M., Iguchi M., Sano H., Murayama T., Arai H., Oida H., Yurugi-Kobayashi T., Yamashita JK, Katagiri H., Majima M., Yokode M., Kita T., Narumiya S.: Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114:784-794, 2004.
65. Koki A., Khan NK, Woerner BM, Dannenberg AJ, Olson L., Seibert K., Edwards D., Hardy M., Isakson P., Masferrer JL: Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 507:177-184, 2002.
66. Kowala MC, Mazzucco CE, Hartl KS, Seiler SM, Warr GA, Abid S., Grove RI: Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters: octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor production. Arterioscler Thromb 13:435-444, 1993.
67. Krotz F., Schiele TM, Klauss V., Sohn HY: Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 42: 312-324, 2005.
68. Lal A., Sharma ML: Failure to reduce experimental myocardial infarct size with ibuprofen pre-treatment in rats. Indian J Physiol Pharmacol 36:133-134, 1992.
69. LaPointe MC, Mendez M., Leung A., Tao Z., Yang XP: Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 286:1416-1424, 2004.
70. Liu GS, Stanley AW, Downey J.: Cyclooxygenase products are not involved in the protection against myocardial infarction afforded by preconditioning in rabbit: cyclooxygenase pathway's involvement in preconditioning. Am J Cardiovasc Pathol 4:157-164, 1992.
71. Manohar M., Goetz TE, Griffin R., Sullivan E.: Pulmonary vascular pressures of strenuously exercising thoroughbreds after administration of phenylbutazone. Am J Vet Res 57:1354-1358, 1996.
72. Marcus AJ, Broekman MJ, Pinsky DJ: COX inhibitors and thromboregulation. N Engl J Med 347:1025-1026, 2002.
73. McClelland S., Gawaz M., Kennerknecht E., Konrad CS, Sauer S., Schuerzinger K., Massberg S., Fitzgerald DJ, Belton O.: Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis 202:84-91, 2009.
74. Meyer-Kirchrath J., Martin M., Schooss C., Jacoby C., Flogel U., Marzoll A., Fischer JW, Schrader J., Schror K., Hohlfeld T.: Over-expression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heart. Cardiovasc Res 81:310-318, 2009.
75. Moubayed SP, Heinonen TM, Tardif JC: Anti-inflammatory drugs and atherosclerosis. Curr Opin Lipidol 18:638-644, 2007.
76. Mousa SA, Brown R., Thoolen MJ, Smith RD: Evaluation of the effect of azapropazone on neutrophil migration in regional myocardial ischaemia/reperfusion injury in rabbits. Br J Pharmacol 100:379-382, 1990.
77. Mousa SA, Cooney JM, Thoolen MJ, Timmermans PB: Myocardial cytoprotective efficacy of azapropazone in a canine heart model of regional ischemia and reperfusion. J Cardiovasc Pharmacol 14:542-548, 1989.
78. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., Ichikawa A., Aze Y., Tanaka T., Yoshida N., Ueno A., Oh-ishi S., Narumiya S.: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388:678-682, 1997.
79. Muscara MN, Vergnolle N., Lovren F., Triggle CR, Elliott SN, Asfaha S., Wallace JL: Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 129:1423-1430, 2000.
80. Olesen M., Kwong E., Meztli A., Kontny F., Seljeflot I., Arnesen H., Lyngdorf L., Falk E.: No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J 36:362-367, 2002.
81. Parente L., Perretti M.: Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 65:153-159, 2003.
82. Pratico D., Tillmann C., Zhang ZB, Li H., FitzGerald GA: Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A 98:3358-3363, 2001.
83. Radi ZA: Pathophysiology of cyclooxygenase inhibition in animal models. Toxicol Pathol 37:34-46, 2009.
84. Radi ZA, Khan NK: Effects of cyclooxygenase inhibition on the gastrointestinal tract. Exp Toxicol Pathol 58:163-173, 2006.
85. Richter CM, Godes M., Wagner C., Maser-Gluth C., Herzfeld S., Dorn M., Priem F., Slowinski T., Bauer C., Schneider W., Neumayer HH, Kurtz A., Hocher B.: Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens 22:191-198, 2004.
86. Ross R.: Rous-Whipple Award Lecture: atherosclerosis: a defense mechanism gone awry. Am J Pathol 143:987-1002, 1993.
87. Rossi P., Kuukasjarvi P., Riutta A., Salenius JP, Tarkka M., Mucha I., Kerttula T., Alanko J.: Prostacyclin and thromboxane A2 synthesis are increased in acute lower limb ischaemia. Prostaglandins Leukot Essent Fatty Acids 55:433-436, 1996.
88. Rossoni G., Muscara MN, Cirino G., Wallace JL: Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol 135:1540-1546, 2002.
89. Rott D., Zhu J., Burnett MS, Zhou YF, Zalles-Ganley A., Ogunmakinwa J., Epstein SE: Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol 41:1812-1819, 2003.
90. Saito T., Rodger IW, Hu F., Robinson R., Huynh T., Giaid A.: Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol 37:71-77, 2004.
91. Saito T., Rodger IW, Hu F., Shennib H., Giaid A.: Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 273:772-775, 2000.
92. Saito T., Rodger IW, Shennib H., Hu F., Tayara L., Giaid A.: Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor. Can J Physiol Pharmacol 81:114-119, 2003.
93. Seta F., Chung AD, Turner PV, Mewburn JD, Yu Y., Funk CD: Renal and cardiovascular characterization of COX-2 knockdown mice. Am J Physiol Regul Integr Comp Physiol 296:1751-1760, 2009.
94. Shizukuda Y., Miura T., Ishimoto R., Itoya M., Iimura O.: Effect of prednisolone on myocardial infarct healing: characteristics and comparison with indomethacin. Can J Cardiol 7:447-454, 1991.
95. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182, 2000.
96. Srisawat S., Phivthong-Ngam L., Unchern S., Chantharaksri U., Govitrapong P., Sanvarinda Y.: Improvement of vascular function by chronic administration of a cyclo-oxygenase inhibitor in cholesterol-fed rabbits. Clin Exp Pharmacol Physiol 30:405- 412, 2003.
97. Stanfield KM, Khan KN, Gralinski MR: Localization of cyclooxygenase isozymes in cardiovascular tissues of dogs treated with naproxen. Vet Immunol Immunopathol 80:309- 314, 2001.
98. Stemme V., Swedenborg J., Claesson H., Hansson GK: Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 20:146-152, 2000.
99. Straino S., Salloum FN, Baldi A., Ockaili RA, Piro M., Das A., Qureshi IZ, Biasucci LM, Capogrossi MC, Biondi-Zoccai GG, Severino A., Mellone P., Crea F., Vetrovec GW, Kukreja RC, Abbate A.: Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol 50:571-577, 2007.
100. Streicher JM, Wang Y.: The role of COX-2 in heart pathology. Cardiovasc Hematol Agents Med Chem 6:69-79, 2008.
101. Such L., Morcillo EJ, Fortana A., Alberola A., Vina J.: Effects of antiinflammatory drugs in a model of acute transmural infarction in the dog. J Pharmacol 14:283-293, 1983.
102. Tang EH, Vanhoutte PM: Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiol Genomics 32:409-418, 2008.
103. Testa M., Rocca B., Spath L., Ranelletti FO, Petrucci G., Ciabattoni G., Naro F., Schiaffino S., Volpe M., Reggiani C.: Expression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodents. J Appl Physiol 103:1412-1418, 2007.
104. Timmers L., Sluijter JP, Verlaan CW, Steendijk P., Cramer MJ, Emons M., Strijder C., Grundeman PF, Sze SK, Hua L., Piek JJ, Borst C., Pasterkamp G., de Kleijn DP: Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 115:326-332, 2007.
105. van der Hoorn JW, Jukema JW, Bekkers ME, Princen HM, Corda S., Emeis JJ, Steendijk P.: Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). Crit Care Med 36:2576-2582, 2008.
106. Vaneckova I., Skaroupkova P., Dvorak P., Certikova Chabova V., Tesar V., Bader M., Ganten D., Kramer HJ: Effects of sodium restriction and cyclooxygenase-2 inhibition on the course of hypertension, proteinuria and cardiac hypertrophy in Ren-2 transgenic rats. Physiol Res 54:17-24, 2005.
107. Wainwright CL, Miller AM, Work LM, Del Soldato P.: NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. Br J Pharmacol 135:1882-1888, 2002.
108. Wang D., Patel VV, Ricciotti E., Zhou R., Levin MD, Gao E., Yu Z., Ferrari VA, Lu MM, Xu J., Zhang H., Hui Y., Cheng Y., Petrenko N., Yu Y., FitzGerald GA: Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci U S A 106:7548-7552, 2009.
109. Whelton A., Fort JG, Puma JA, Normandin D., Bello AE, Verburg KM: Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 8:85-95, 2001.
110. Whelton A., White WB, Bello AE, Puma JA, Fort JG: Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90:959-963, 2002.
111. White WB, Faich G., Whelton A., Maurath C., Ridge NJ, Verburg KM, Geis GS, Lefkowith JB: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 89:425-430, 2002.
112. Wilner KD, Rushing M., Walden C., Adler R., Eskra J., Noveck R., Vargas R.: Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 42:1027-1030, 2002.
113. Wong E., Huang JQ, Tagari P., Riendeau D.: Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 157:393-402, 2001.
114. Wu D., Mennerich D., Arndt K., Sugiyama K., Ozaki N., Schwarz K., Wei J., Wu H., Bishopric NH, Doods H.: The effects of microsomal prostaglandin E synthase-1 deletion in acute cardiac ischemia in mice. Prostaglandins Leukot Essent Fatty Acids 81:31-33, 2009.
115. Zadelaar S., Kleemann R., Verschuren L., de Vries-Van der Weij J., van der Hoorn J., Princen HM, Kooistra T.: Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27:1706-1721, 2007.
116. Zidar N., Dolenc-Strazar Z., Jeruc J., Jerse M., Balazic J., Gartner U., Jermol U., Zupanc T., Stajer D.: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the normal human heart and in myocardial infarction. Cardiovasc Pathol 16:300-304, 2007.
117. Zidar N., Odar K., Glavac D., Jerse M., Zupanc T., Stajer D.: Cyclooxygenase in normal human tissues: is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med, 2008.